Clinical Trial Update: Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial testing large fraction radiotherapy in combination with lenalidomide and glofitamab for relapsed/refractory diffuse large B-cell lymphoma; recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Columvi (glofitamab)
• Revlimid (lenalidomide)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Diffuse Large B-cell Lymphoma, Relapsed and Refractory | Phase 2 | Status: RECRUITING